Citadel Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-39,800
| Closed | -$191K | – | 14835 |
|
|
2021
Q1 | $191K | Buy |
39,800
+24,400
| +158% | +$127K | ﹤0.01% | 11758 |
|
|
2020
Q4 | $67K | Buy |
+15,400
| New | +$65.9K | ﹤0.01% | 10451 |
|
|
2020
Q1 | – | Sell |
-29,000
| Closed | -$110K | – | 10462 |
|
|
2019
Q4 | $110K | Buy |
29,000
+17,500
| +152% | +$83.8K | ﹤0.01% | 8509 |
|
|
2019
Q3 | $59K | Buy |
11,500
+900
| +8% | +$5.56K | ﹤0.01% | 8660 |
|
|
2019
Q2 | $66K | Sell |
10,600
-400
| -4% | -$2.3K | ﹤0.01% | 8658 |
|
|
2019
Q1 | $78K | Sell |
11,000
-500
| -4% | -$4.5K | ﹤0.01% | 8649 |
|
|
2018
Q4 | $98K | Sell |
11,500
-15,600
| -58% | -$203K | ﹤0.01% | 8245 |
|
|
2018
Q3 | $543K | Buy |
27,100
+7,900
| +41% | +$186K | ﹤0.01% | 6564 |
|
|
2018
Q2 | $496K | Sell |
19,200
-10,600
| -36% | -$294K | ﹤0.01% | 6386 |
|
|
2018
Q1 | $712K | Buy |
29,800
+17,200
| +137% | +$542K | ﹤0.01% | 5302 |
|
|
2017
Q4 | $427K | Sell |
12,600
-1,400
| -10% | -$39.1K | ﹤0.01% | 5894 |
|
|
2017
Q3 | $296K | Buy |
+14,000
| New | +$257K | ﹤0.01% | 6096 |
|
|
2016
Q1 | – | Sell |
-2,200
| Closed | -$62K | – | 8412 |
|
|
2015
Q4 | $62K | Buy |
+2,200
| New | +$37K | ﹤0.01% | 7132 |
|
Citadel Advisors's ADMS Position: Q4 2021 in Review
Citadel Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 27,776 shares — an estimated $136K sold.
Citadel Advisors first reported a position in ADMS in Q3 2014 and held it in 23 quarters. The position peaked at $16.5M in Q3 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Citadel Advisors reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Citadel Advisors sold 27,776 Adamas Pharmaceuticals shares in Q4 2021, an estimated $136K.
- Citadel Advisors first reported a position in Adamas Pharmaceuticals in Q3 2014 and held it in 23 quarters.
- Citadel Advisors's Adamas Pharmaceuticals position peaked at $16.5M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.